IONS IONIS PHARMACEUTICALS INC
Price Chart
Executive Summary
Ionis Pharmaceuticals appointed Ludwig Hantson, Ph.D. to its Board of Directors effective June 4, 2026, and reported shareholder approval of an amendment to increase the 2011 Equity Incentive Plan by 9.5 million shares to 52 million total shares, as well as an amendment to the 2000 Employee Stock Purchase Plan. No financial results or guidance were provided, and the changes are routine governance items.
Actionable Insight
The board appointment adds significant biopharma experience but provides no near-term trading catalyst. Monitor upcoming commercial launches and pipeline milestones for future signals; the equity plan increase authorizes potential dilution but is standard for a growing biotech.
Key Facts
- Ludwig Hantson appointed to Board effective June 4, 2026
- Shareholders approved an increase of 9,500,000 shares under the 2011 Equity Incentive Plan to an aggregate of 52,000,000 shares
- Shareholders approved an amendment to the 2000 Employee Stock Purchase Plan increasing authorized shares by 750,000 and removing the termination date
- Two long-serving directors, Joseph Wender and Lynne Parshall, recently retired
Financial Impact
No financial impact reported in this filing
Risk Factors
- Potential dilution from future equity grants under the increased share authorization
- Execution risk on two planned commercial launches this year
Market Snapshot
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001140361-26-024407 |
| Document: ef20075669_ex99-1.htm | 0001140361-26-024407 |
| Document: 0001140361-26-024407-index-headers.html | 0001140361-26-024407 |
| Document: 0001140361-26-024407-index.html | 0001140361-26-024407 |
| Document: 0001140361-26-024407.txt | 0001140361-26-024407 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 12, 2026
2d ago
|
8-K
| $73.26 awaiting T+5 | awaiting T+5 | — | $73.28 (+0.03%) |
|
Jun 8, 2026
6d ago
|
8-K
| $73.76 awaiting T+5 | awaiting T+5 | — | $73.28 (−0.65%) |
|
May 28, 2026
17d ago
|
8-K
| $77.27 $75.09 | ▼ −2.82% | ▼ −3.14% | $73.28 (−5.17%) |
|
Apr 28, 2026
6w ago
|
Insider Cluster
| $71.50 $75.20 | ▲ +5.17% | ▲ +3.48% | $73.28 (+2.49%) |
|
Apr 21, 2026
7w ago
|
8-K
| $74.71 $71.50 | ▼ −4.30% | ▼ −5.38% | $73.28 (−1.92%) |
|
Apr 16, 2026
8w ago
|
Insider Cluster
| $75.25 $74.06 | ▼ −1.58% | ▼ −2.57% | $73.28 (−2.62%) |
|
Feb 25, 2026
15w ago
|
8-K
| $80.87 $79.25 | ▼ −2.00% | ▼ −0.90% | $73.28 (−9.39%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access